Event Calendar

Electrostatic Assembly for Nanoparticle Targeting of Cells and Tissues- Professor Paula Hammond (MIT) @ Online
Jan 20 @ 12:00 pm – 1:00 pm
On Wednesday, January 20 from 12-1PM (Eastern Time), the Department of Chemical Engineering & Applied Chemistry will be hosting a virtual lecture with Professor Paula Hammond from the Massachusetts Institute of Technology (MIT) titled Electrostatic Assembly for Nanoparticle Targeting of Cells and Tissues. Please see below for more information about the lecture and to RSVP to attend the event: Register to attend the online event: https://forms.office.com/Pages/ResponsePage.aspx?id=JsKqeAMvTUuQN7RtVsVSEHCnTLY289tMkupbxVf9ad5UOTZCVTE4MTkxWllSQlRXU1FVVTNJNUFYWS4u   Graduate students are welcome to attend a graduate student Q&A session with Professor Hammond on Thursday, January 21 from 1-2PM (Eastern Time). Register to attend the Q&A session: uoft.me/Hammond   Abstract Nanomaterials of many types have been applied to address biomedical challenges, particularly in the delivery of drug to targeted regions of the body.  One of the most powerful interactions that can regulate tissue transport and nanomaterial trafficking is electrostatic charge. In our lab, we have used electrostatic assembly methods in conjunction with well-defined charged macromolecules to enable delivery of drug to specific tissues or organs based on a combination of multivalent charge interactions coupled with other secondary non-specific or specific binding interactions. These systems vary from highly designed synthetic vectors that can deliver  mRNA and even gene editing systems to electrostatically assembled complexes that can be generated with a great deal of control. The generation of such systems requires, in each case, a tuning of the ratio of charged species, and an ability to direct responsive behavior that enables release in such systems. In one approach, a layer-by-layer (LbL) technique toward construction of nanostructured nanoparticles provides multiple advantages for chemotherapy. We have generated LbL outer layers that provide effective stealth properties, with long systemic plasma blood half lives and higher tumor accumulation over time. We have demonstrated efficacy in genetically induced non-small cell lung cancer mouse models in which key siRNA targets have been selected with chemotherapy drug in the same nanoparticle system, and are now examining new siRNA and drug combinations in ovarian cancer. By staging release of different drug components via the adaptation of the nanoparticle structure, we can achieve highly synergistic release behavior in these systems. We have found that certain LbL nanoparticle formulations traffic differently in cells based on the negatively charged polypeptide, and are exploring ways to utilize these differences in affinity for more selective tumor cell binding and deliver within cells.   Ongoing work that includes new ovarian cancer and lymphoma efforts utilizing siRNA and combination drug therapies will be discussed, including new work involving the delivery of cytokines for activation of the immune system against cancer.   Bio Professor Paula T. Hammond is the David H. Koch Chair Professor of Engineering at the Massachusetts Institute of Technology, Head of the Department of Chemical Engineering and a member of MIT’s Koch Institute for Integrative Cancer Research. Her research in nanomedicine encompasses the development of new biomaterials to enable drug delivery from surfaces with spatio-temporal control. She also investigates novel responsive polymer architectures for targeted nanoparticle drug and gene delivery. She is known for her work on nanoparticles to target cancer, and thin film coatings to release factors that regenerate bone and assist in wound healing.   Professor Paula Hammond was elected to the National Academy of Science in 2019, the National Academy of Engineering in 2017, the National Academy of Medicine in 2016, and the 2013 Class of the American Academy of Arts and Sciences.  She has also recently received the AIChE Margaret Rousseau Award. Professor Hammond has published over 330 papers, and over 20 patent applications. She is the co-founder and member of the Scientific Advisory Board of LayerBio, Inc. and a member of the Scientific Advisory Board of Moderna Therapeutics.   Any questions regarding the lecture can be directed to Amanda Hacio (Communications Officer & External Relations Liaison, Department of Chemical Engineering & Applied Chemistry) at amanda.hacio@utoronto.ca
Princess Margaret Seminar Series- “Taking control of innate immunity with nanobiologic therapeutics” @ Online
Jan 21 @ 12:00 pm – 1:00 pm

Thursday, January 21 2021 | 12:00 – 1:00pm

Topic: “Taking control of innate immunity with nanobiologic therapeutics”

Presenter: William J.M. Mulder, Ph.D.
Professor of Radiology and Oncological Sciences at Icahn
School of Medicine at Mount Sinai (IMMS) New York
Professor of Precision Medicine at the Eindhoven University of Technology (TU/e),
The Netherlands

Host: Dr. Gang Zheng

Join the Zoom Meeting HERE – Password: 857896

ECHO Webinar – Discover, Develop, Deliver: Building a Successful Start-Up in the Midst of a Pandemic @ Online
Jan 26 @ 11:00 am – 12:00 pm

Title: Discover, Develop, Deliver: Building a Successful Start-Up in the Midst of a Pandemic

Date & Time: Tuesday, Jan 26, 2021 11:00 am – 12:00 pm

Speaker: Wendy Naimark, PhD


Dr. Naimark is one of the founders of Ripple Therapeutics (RIPL) following its spin out from Interface Biologics (IBI) in 2020. Dr. Naimark has been leading teams in the
development of local drug delivery products for over 20 years. She joined IBI in 2016 and led the Research & Development of both Epidel and Kinesyx technology teams and partner projects. Prior to joining IBI, Dr. Naimark led the Clinical Program for the development of a drug-eluting, self-expanding, biodegradable scaffold at 480 Biomedical. Dr. Naimark began her industry career at Boston Scientific in the Corporate R&D group, which developed the TAXUS® Drug Eluting Stent. At Boston Scientific her work spanned developing combination products to deliver angiogenic biological agents to leading Regulatory Submission Strategies for approval of Class III combination products. Dr. Naimark received her PhD in Biomaterials from the University of Toronto and began developing her career interest in local drug delivery at Caltech during her post-doctoral fellowship. Dr. Naimark is an inventor of 29 patents in the local drug delivery field.


Ripple Therapeutics is a clinical stage company focused on improving ophthalmic therapeutics with controllable, sustained drug delivery. Ripple’s Epidel® technology platform is based on a discovery that drugs can be engineered into controlled release pharmaceuticals without polymers or excipients. https://www.rippletherapeutics.com/

Join the webinar:

Meeting ID: 880 8267 5085; Password: xDHR1g

For event poster click here

Lecture Title TBA- Eli Sone @ Online
Feb 9 @ 12:00 pm – 1:00 pm

Portrait of Eli Sone

Title: TBA

Presenter: Eli Sone

Date: February 9th 2021

Time: 12:00pm – 1:00pm

Meeting Link: TBA


Abstract: TBA

Lecture Title TBA- Shyni Varghese @ Online
Mar 9 @ 12:00 pm – 1:00 pm

Title: TBA

Presenter: Shyni Varghese

Date: March 9th 2021

Time: 12:00pm – 1:00pm

Meeting Link: TBA


Abstract: TBA

Lecture Title TBA- Lena Ting @ Online
Apr 13 @ 12:00 pm – 1:00 pm

Title: TBA

Presenter: Lena Ting

Date: April 13th 2021

Time: 12:00pm – 1:00pm

Meeting Link: TBA


Abstract: TBA


External Event Calendars

© 2020 Faculty of Applied Science & Engineering